History of hypertension and enhanced thrombogenic activity in postinfarction patients

Hypertension

Volumn 41, Issue 4, 2003, Pages 943-949

  Fadl, Yazid Y ^a   Zareba, Wojciech ^a   Moss, Arthur J ^a   Marder, Victor J ^b   Sparks, Charles S ^a   Miller Watelet, Luc F ^a   Carroll, Elizabeth R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibrinogen; Hemostasis; Hypertension, chronic; Lipids; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; THROMBOGENESIS; THROMBOSIS;

EID: 0037389635     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000061120.23237.D9     Document Type: Article

References (24)

1. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
2. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D. O'Leary DH, Bryan RN, Anderson M, Lumlcy T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001;161:1183-1192.
3. Cullen P, Assmann G. Primary prevention of coronary heart disease: from controversy to consensus. Nutr Metab Cardiovasc Dis. 2000;10:143-153.
4. Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens. 1998;16:577-583.
5. Wilson PW. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Am J Cardiol. 1997;80:3J-8J.
6. Emeriau JP, Decamps A, Manciet G, Dupuy-Braud E, Galley P. Hypertension in the elderly. Am J Med. 1988;84:92-97.
7. Kannel WB, Schatzkin A. Risk factor analysis. Prog Cardiovasc Dis. 1984;26:309-332.
8. Haider AW, Chen L, Larson MG, Evans JC, Chen MH, Levy D. Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction. Hypertension. 1997;30:1020-1024.
9. Cushman M, Yanez D, Psaly BM, Fried LP, Heiss G, Lee M, Polak JF. Savage PJ, Tracy RP. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study: Cardiovascular Health Study Investigators. Am J Epidemiol. 1996;143:665-676.
10. Moss AJ, Goldstein R, Marder VJ, Sparks C, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown M, Liang C, for the THROMBO Research Group. Thrombogenic factors and recurrent cardiac events. Circulation. 1999;99:2517-2522.
11. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
12. Palmieri V, Celentano A, Roman MJ, de Simone G, Lewis MR. Best L, Lee ET, Robbins DC, Howard BV, Devereux RB. Fibrinogen and preclinical echocardiographic target organ damage: the strong heart study. Hypertension. 2001;38:1068-1074.
13. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension. 2000;36:978-985.
14. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H. Cupples LA, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham heart study. Hypertension. 2000;36:477-483.
15. Retterstol L, Kierulf P, Pedersen JC, Bohn M, Bakken A, Erikssen J, Berg K. Plasma fibrinogen level and long-term prognosis in Norwegian middle-aged patients with previous myocardial infarction. A 10 year follow-up study. J Intern Med. 2001;249:511-518.
16. Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients: the Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol. 1995;48:757-765.
17. Cremer P, Nagel D, Mann H, Labrot B, Muller-Berninger R, Elster H, Seidel D. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997;129:221-230.
18. Held C, Hjemdahl P, Hakan WN, Bjorkander I, Forslund L, Wiman B, Rehnqvist N. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris: results from the APSIS study: the Angina Prognosis Study in Stockholm. Atherosclerosis. 2000;148:179-188.
19. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
20. Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease: potential effects of β-blockade. Circulation. 1991;84(suppl V):V-I72-V-I77.
21. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
22. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
23. Casiglia E, Mazza A, Tikhonoff V, Pavei A, Privato G, Schenal N, Pessina AC. Weak effect of hypertension and other classic risk factors in the elderly who have already paid their toll. J Hum Hypertens. 2002;16:21-31.
24. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.